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Classification 
The 2005 World Health Organization (WHO) 
classification of SGTs is complex and comprises 10 
benign and 23 malignant entities of epithelial origin. 
Non epithelial neoplasms are rare, representing about 
2-5% of SGTs, and will not be discussed herein. They 
include, among others, haemangioma, lymphangioma, 
schwannoma, neurofibroma, lipoma, sarcoma, 
lymphoma, and metastatic lesions (which develop 
preferentially in the parotid glands, and are most often 
of squamous cell origin). The diversity of epithelial 
SGTs as well as their rarity and varied morphological 
aspects often makes diagnosing such neoplasms 
difficult. Most primary epithelial SGTs occur in the 
parotid glands; about 10% occur in the submandibular 
glands, and less than 1% develops in the sublingual 
glands. Minor glands are involved in 9-23% of SGT 
cases. Between 54 and 79% of all tumors are benign, 
and 21 to 46% are malignant. Most SGTs occurring in 
the sublingual glands are malignant (70-90%). Fifteen 
to 32% of parotid tumors, and about 40% of 
submandibular lesions are carcinomas. Finally, 50% of 
minor gland neoplasms are cancers. Notably, SGTs of 
the tongue, floor of the mouth and retromolar areas are 
most often malignant. Overall, pleomorphic adenoma is 
the most frequent SGT, comprising about 50-60% of 
cases. The second most frequent benign SGT is 
Warthin tumor. Mucoepidermoid carcinoma is the most 
common malignant SGT. Histological types vary in 
frequency according to location. Pleomorphic 
adenoma, Warthin tumor, and mucoepidermoid 
carcinoma are commonly found in the parotid glands 
whereas polymorphous low-grade adenocarcinoma 
usually arises in minor glands.  
2005 WHO classification of epithelial SGTs 
Benign epithelial tumors 
- Pleomorphic adenoma  
- Myoepithelioma  
- Basal cell adenoma  
- Warthin tumor  
- Oncocytoma  
- Canalicular adenoma  
- Sebaceous adenoma  
- Lymphadenoma  
- Ductal papilloma  
- Cystadenoma  
Malignant epithelial tumors 
- Acinic cell carcinoma  
- Mucoepidermoid carcinoma  
- Adenoid cystic carcinoma  
- Polymorphous low-grade adenocarcinoma  
- Epithelial-myoepithelial carcinoma  
- Clear cell carcinoma, not otherwise specified  
- Basal cell adenocarcinoma  
- Malignant sebaceous tumors  
- Cystadenocarcinoma  
- Low-grade cribriform cystadenocarcinoma  
- Mucinous adenocarcinoma  
- Oncocytic carcinoma  
- Salivary duct carcinoma  
- Adenocarcinoma, not otherwise specified  
- Myoepithelial carcinoma  
- Carcinoma ex pleomorphic adenoma  
- Carcinosarcoma  
- Metastasizing pleomorphic adenoma  
- Squamous cell carcinoma  
- Small cell carcinoma  
- Large cell carcinoma  
- Lymphoepithelial carcinoma  
- Sialoblastoma  
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Because of the morphological diversity of SGTs and 
the rarity of some subtypes, only the most frequent 
entities (i.e. pleomorphic adenoma, Warthin tumor, and
mucoepidermoid carcinoma) will be discussed in detail 
herein. Other less frequent entities will be mentioned 
briefly. 
Clinics and pathology 
Disease 
Salivary gland tumors (SGTs) 
Note 
The salivary glands comprise the three paired major 
glands (the parotid, the submandibular and sublingual) 
and the minor glands (located in the palate, lips, buccal 
mucosa...). Salivary gland tumors (SGTs) are rare 
neoplasms accounting for 0.4-13.5 cases per 100000 
people. Malignant SGTs represent 6% of head and neck 
cancers and 0.3% of all cancers in the US. Still in the 
US, carcinomas of the major salivary glands comprise 
11% of oropharyngeal neoplasms. On the whole, SGTs 
predominantly arise in female patients, but the sex ratio 
varies according to tumor type. The average age of 
patients with SGT is about 45 years old. The peak 
incidence of most specific types is in the 6th and 7th 
decades. However, the highest incidence of 
pleomorphic adenoma (PA), mucoepidermoid 
carcinoma (MEC), and acinic cell carcinoma is in the
third and fourth decades. In the pediatric population, 
the most common malignant SGT is mucoepidermoid 
carcinoma. Mesenchymal neoplasms are more frequent 
in this age group compared to the adult population and
epithelial tumors are more often malignant. 
Etiology 
The etiology of SGTs is so far unknown. Putative risk 
factors include cigarette smoking, genetic 
predisposition, viral infections, rubber manufacturing, 
plumbing, some types of woodworking, as well as 
asbestos mining, exposure to nickel compounds, and 
cellular phone use. The only well-established risk 
factor is ionizing radiation. Atomic bomb survivors and 
cancer patients treated by radiation present with a 
substantially higher risk of developing SGTs. However, 
there is a strong association between Warthin tumor 
(WT) and cigarette smoking, with WT occurring 8 
times more often in smokers than in non-smokers. 
Irritants in tobacco smoke may cause metaplasia in the 
parotid gland. The association with tobacco use may 
explain the higher incidence of WT in males. 
Cytogenetics 
A growing number of both benign and malignant SGTs 
are characterized by recurrent genetic alterations, 
particularly chromosome translocations. Specific 
chromosomal rearrangements are commonly found in 
malignant hematopoietic proliferations as well as in 
sarcomas, but less than 1% of all epithelial cancers are 
characterized by such distinct, recurrent genomic 
anomalies. Those anomalies may serve as diagnostic, 
prognostic and/or predictive markers in SGTs and their 
identification may complement the morphologic 
evaluation. Chromosome translocations in SGTs result 
in pathogenetically relevant fusion oncogenes. Those 
genes encode novel fusion proteins as well as 
ectopically expressed normal or truncated proteins that 
may play a role in tumor initiation and/or progression. 
Treatment 
Radical surgical excision is the cornerstone treatmnt 
of SGTs. 
Prognosis 
Prognosis correlates most strongly with clinical stage, 
emphasizing the importance of early diagnosis. 
Optimal initial surgery minimizes the risk of local 
recurrence, hence the risk of distant metastases.  
The tumor type and microscopic grade have been 
shown to be independent predictors of behavior. Acinic 
cell carcinoma, basal cell adenocarcinoma, clear cell 
adenocarcinoma, and epithelial-myoepithelial 
carcinoma are all low-grade neoplasms whereas 
salivary duct carcinoma, oncocytic carcinoma, 
primitive epidermoid carcinoma, and undifferentiated 
carcinoma are high-grade tumors. The site of 
occurrence is also an important prognostic factor. 
Patients with MEC of the parotid gland have a better 
prognosis than those with submandibular gland tumors 
of the same grade. With some other tumor types, both a 
younger age and female gender are associated with a 
better outcome. Facial nerve paralysis appears to 
predict both recurrence and decreased survival. 
Disease 
Pleomorphic adenoma (PA) 
Clinics 
PA is typically a slowly growing, asymptomatic, 
discrete nodule most often located in the superficial 
lobe of the parotid gland. It is usually mobile with 
palpation, and rarely causes facial paralysis due to 
extrinsic compression of the VII cranial nerve. 
Pathology 
Pleomorphic adenoma is a benign epithelial tumor most 
often arising in the parotid gland.  
 
Pleomorphic adenoma HEx100. 
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It may also occur in the submandibular and minor 
salivary glands. Microscopically, PA is characterizd 
by its morphological diversity. It comprises epithelial 
and myoepithelial cells variably arranged in a mucoid, 
myxoid or chondroid background. Epithelial cell types 
observed in PA include cuboidal, basaloid, squamous, 
clear, and spindle cells. The epithelial component may 
predominate and in this instance the lesion is called 
"cellular PA". The myoepithelial component may form 
a fine reticular pattern or sheets of spindle cells. The 
mesenchymal tissue is mucoid, myxoid or chondroid, 
and predominates in some instances. Osseous 
metaplasia or lipomatous differentiation may be seen. 
PA usually presents with a variably thick capsule that 
on serial sectioning may be focally absent. The lesion 
typically harbors few mitoses and cytological atypia. 
Although PA is a benign tumor, it may recur and/or 
undergo malignant transformation.  
Histogenesis: PA has been shown to be of monoclonal 
origin. A common single cell may give rise to epithelial 
and modified myoepithelial cells, as well as 
mesenchymal elements. The two components may 
share a common origin from a single uncommitted cell 
(e.g. pluripotent intercalated duct cell) that may 
differentiate along epithelial and mesenchymal cell 
lines. Alternatively, PA could develop from committed 
progenitor cells, e.g. epithelial basal ductal cells. Upon 
neoplastic transformation, some of those cells may 
undergo divergent differentiation and acquire a 
mesenchymal phenotype. 
Cytogenetics 
Pleomorphic adenoma presents with a highly specific 
and recurrent pattern of chromosome abnormalities. 
Four major cytogenetic subgroups have been defined: 
rearrangements involving 8q12 (39%), with the 
t(3;8)(p21;q12) translocation representing about half 
the cases; rearrangements of 12q13-15 (8%); sporadic 
clonal changes involving chromosomal segments other 
than 8q12 or 12q13-15 (23%), and an apparently 
normal karyotype (30%). 
Rearrangements of chromosome 8q12 in PA most often 
involve the 5' non-coding region of PLAG1 
(pleomorphic adenoma gene-1). Translocations 
involving 8q12 result in promoter swapping between 
PLAG1 and an ubiquitously expressed gene, leading to 
activation of PLAG1 expression. The translocation 
partners most often involved are CTNNB1 (encoding 
beta-1 catenin) and LIFR (leukemia inhibitory factor 
receptor), resulting from translocations t(3;8)(p21;q12) 
and t(5;8)(p13;q12), respectively.  
PLAG1 is a developmentally regulated zinc finger gene 
that maps to 8q12. It is not expressed in normal 
salivary gland parenchyma. The gene product is a 
nuclear protein that functions as a DNA-binding 
transcription factor. Potential PLAG1 binding sites 
have been found in promoter 3 of the IGF-II (insulin-
like growth factor II) gene. It was shown that PLAG1 
bound IGF-II promoter 3 and stimulated its activity. 
IGF-II was highly expressed in PAs with up-regulated 
PLAG1 gene. Conversely, IGF-II up-regulation was 
neither detected in PAs without abnormal PLAG1 
expression, nor in normal salivary gland parenchyma. 
Thus, IGF-II is a potential PLAG1 target gene. PLAG1 
may play a role in PA pathogenesis by inducing growth 
factor production, hence cell proliferation. It was 
demonstrated by Western blot and 
immunohistochemical analyses that PLAG1 expression 
was up-regulated in epithelial and myoepithelial cel s, 
as well as in the mesenchymal component of PA.  
Another mechanism of gene fusion involving PLAG1 
is formation of chromosome 8 rings harboring 
amplification of a pericentromeric segment with 
breakpoints in the FGFR1 gene at 8p12 and in the 
PLAG1 gene at 8q12.1. Such r(8)(p12q12.1) rings 
result in a novel FGFR1-PLAG1 gene fusion. The 
breakpoints occur in the 5' non coding regions of both 
genes, leading to promoter substitution and activation 
of PLAG1 expression.  
Cryptic, intrachromosomal 8q rearrangements have 
been reported in PAs with an apparently normal 
karyotype. In PLAG1-CHCHD7 gene fusions, exon 1 
of CHCHD7 (coiled-coil-helix-coiled-coil-helix 
domain 7) was fused to either exons 3-4 or 2-4 of 
PLAG1, resulting in up-regulated PLAG1 protein 
expression. CHCHD7 maps to chromosome 8q12, 500 
bp telomeric to PLAG1. It is a newly identified 
member of a multifamily of proteins containing a 
conserved coiled-coil-helix-coiled-coil-helix domain. 
CHCHD7 gene is ubiquitously expressed and its 
function has yet to be discovered.  
TCEA1 (transcription elongation factor A 1, also 
known as SII) is another potential fusion partner of 
PLAG1 in cryptic 8q rearrangements. The TCEA1-
PLAG1 fusion transcript is formed by fusion of exon 1 
of TCEA1 to exon 2 or 3 of PLAG1. TCEA1 is an 
intronless, ubiquitously expressed pseudogene that 
maps to chromosome 3p21.3-22 (to the same region as 
CTNNB1). Transcription elongation factors are 
involved in the regulation of the transcription of most 
protein-coding genes. TCEA1 releases RNA 
polymerase II from transcriptional arrest due to specific 
DNA sequences or DNA-binding proteins.  
The mechanism of such cryptic 8q rearrangements may 
be a promoter substitution resulting from a 
nonreciprocal rearrangement such as an insertion.  
The target gene in 12q13-15 rearrangements is 
HMGA2 (high motility group 2, also known as 
HMGIC). It maps to 12q14.3 and encodes a small non-
histone, chromatin-associated protein that can modulate 
transcription by altering the chromatin architecture. 
The highest expression levels of HMGA2 gene are 
detected in fetal tissues whereas gene expression i 
undetectable in normal adult tissues. The translocations 
involving 12q13-15 generate gene fusions in which the 
5' part of HMGA2 (encoding the three DNA-binding 
domains) are linked to various fusion partner genes. 
Two fusion genes, HMGA2-NFIB (nuclear factor I B 
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gene) and HMGA2-FHIT (fragile histidine triad gene), 
have been identified in PAs with ins(9;12)(p23;q12-15) 
and t(3;12)(p14.2;q14) respectively. Such 
rearrangements lead to separation of the DNA-binding 
domains from the spacer, the carboxy-terminal acidic 
domain, and the entire 3' UTR with its miRNA 
complementary sites. Those sites are targets for the 
miRNA let-7 and their loss through chromosomal 
translocation/truncation disrupts repression of 
HMGA2, leading to increased expression. Such loss of 
regulatory sequences has been demonstrated to promote 
anchorage independent-growth. Thus, HMGA2 gene 
rearrangements may promote tumorigenesis in PA.  
A third fusion partner gene identified in PA is WIF1 
(wnt inhibitory factor 1). Since HMGA2 and WIF1 
genes are located in opposite orientation 0.7 Mb apart, 
the recurrent HMGA2-WIF1 fusions are likely to result 
from a cryptic paracentric inversion.  
Other complex HMGA2 alterations have been 
identified in PA, such as amplifications involving an 
apparently intact HMGA2 sequence, a disrupted gene 
or the HMGA2-WIF1 fusion gene. Amplification in 
addition to gene fusion is a novel mechanism of 
HMGA2 activation. Moreover, high-level expression of 
HMGA2 resulting from gene amplification has been 
suggested to contribute to malignant transformation of 
PA.  
HMGA2 plays an important role in mammalian growth 
(mutations of the mouse gene causes the "pygmy" 
phenotype) and may be a key player in PA 
development and progression. PLAG1 gene exerts 
oncogenic effects by inducing growth factor 
production. In opposition, the pathogenetic relevance of 
the fusion partners of those genes remains to be 
elucidated. The diversity in chromosomal segments that 
participate in the translocations and the absence of a 
common structural or functional denominator in those 
segments suggest that their role may be merely to 
provide the necessary elements for proper translation of 
the fusion transcripts. 
The PLAG1- and HMGA2-containing fusion genes 
may be used as diagnostic markers in PA. Detection of 
such genetic hallmarks using RT-PCR or FISH 
technique could help diagnose morphologically 
ambiguous cases. 
Treatment 
Because of the risk of recurrence and malignant 
transformation, radical surgical excision is required. 
Still, whether to perform superficial parotidectomy or 
extra-capsular dissection remains debated. Additional 
surgery in case of recurrence exposes to an increased 
risk of facial nerve injury. 
Prognosis 
The prognosis of pleomorphic adenoma is excellent if 
completely removed. Recurrence rates at 5 year- and 10 
year-follow-up are 3.4% and 6.8%, respectively. 
Disease 
Carcinoma ex pleomorphic adenoma 
Clinics 
Patients present with rapid growth and/or ulceration of 
a known, untreated PA. The mass is usually painless 
but about one third of patients have pain or facial nerve 
paralysis. The lesion may be fixed to underlying soft 
tissues. 
Pathology 
Carcinoma ex PA is a malignant epithelial cell 
proliferation arising in an authentic PA. According to 
the AFIP (Armed Forces Institute of Pathology), it 
represents about 6% of malignant SGTs and develops 
in 9.5% of PAs. Similarly to PA, carcinoma ex PA 
mainly occurs in the parotid gland; it usually develops 
a decade later compared to PA. It may result from 
accumulation of genetic alterations in long-standing 
tumors. Indeed, the risk of malignant transformation 
increases with time. The malignant component may 
totally replace the benign portion of the tumor. It may 
correspond to poorly differentiated adenocarcinoma, 
undifferentiated carcinoma or any other type of 
epithelial malignancy. 
Cytogenetics 
Genomic alterations in carcinoma ex PA are identical 
to those found in PA. Alterations at 12q13-15 with 
amplification of HMGA2 and MDM2 genes have been 
reported. MDM2 (at 12q14-15) is one of the most 
frequently co-amplified genes together with HMGA2, 
suggesting a pathogenetic role for MDM2 in carcinoma 
ex PA. The genes were co-amplified in the same 
homogeneously staining regions and double minute 
chromosomes in a case of carcinoma ex PA with a 
del(5)(q22-23q32-33) and t(10;12)(p15;q15). However, 
there was little MDM2 protein expression, as assessed 
by immunohistochemistry, compared to high HMGA2 
expression levels in the carcinomatous parts of the 
tumor. 
Cerb-B2 surexpression has been detected in one third 
of carcinoma ex PA and could help distinguish it from 
atypical PA. Mutation and overexpression of TP53 are 
also frequent events in carcinoma ex pleomorphic 
adenoma. 
Treatment 
In carcinoma ex PA, the recommended therapy is wide 
local excision with lymph node dissection, followed by 
radiation therapy for widely invasive tumors. 
Prognosis 
The prognosis of carcinoma ex PA depends on its 
extension. Prognosis is excellent when the malignant 
component is confined to the PA nodule whereas it 
may be dismal when carcinoma extends beyond the 
capsule and infiltrates into adjacent soft tissues. 
Capsular penetration of more than 1.5 mm and a high- 
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grade carcinomatous component are associated with 
poor prognosis. Survival rates at 5, 10, 15, and 20 years 
range from 25-65%, 18-50%, 10-35%, and 0-38%, 
respectively. 
Disease 
Warthin tumor (WT) 
Clinics 
WT presents as an asymptomatic, slowly growing, and 
fluctuant mass located in the lower pole of the parotid 
gland. It is clinically multicentric in 12-20% of 
patients, and is bilateral in 5-14%. Additional 
subclinical lesions are found microscopically in 50% of 
cases. WT usually occurs in patients in their seventh 
decade and is rare before age 40. Pain occurs in about 
10% of cases, and facial paralysis is very unusual, 
resulting from inflammation and fibrosis. 
 
Warthin tumor HEx100. 
Pathology 
WT is composed of glandular and often cystic 
structures, sometimes presenting with papillae, lind by 
a bilayered epithelium, comprising inner columnar 
eosinophilic or oncocytic cells and outer smaller basal 
cells. The stroma often contains dense lymphoid tissue 
that may harbor germinal centres and mantle zones. 
WT is also known as cystadenolymphoma, but this 
term should not be used in order to avoid confusion 
with malignant lymphomas. It is almost exclusively 
found in the parotid glands and the periparotid lymph 
nodes. WT is well demarcated by a thin capsule. The 
lesion usually harbors no significant nuclear atypia or 
mitotic activity. Malignant change is rare, at about 1%, 
and may involve the epithelial or lymphoid component. 
The epithelial component may degenerate into 
squamous cell carcinoma, and occasionally into 
mucoepidermoid carcinoma, adenocarcinoma or 
undifferentiated carcinoma. Lymphoma, especially of 
the nodal type, may develop from the lymphoid 
component of WT. 
Histogenesis: WT is thought by some to originate from 
heterotopic salivary ductal inclusions in intra- or peri-
parotid lymph nodes. This hypothesis may explain why  
WT is not observed in salivary glands without 
incorporated lymph nodes. Other authors posit that WT 
is a benign epithelial neoplasm that attracts a marked 
lymphoid reaction, similar to that seen in other salivary 
gland neoplasms. The immunoprofile of the 
lymphocyte subsets is similar to that of lymphocytes in 
normal or reactive lymph nodes. Analysis of the X 
chromosome-linked human androgen receptor gene 
showed that WT is non-clonal, and thus likely to be 
non-neoplastic. According to some, WT may result 
from induction of cystic changes in branchial cleft 
epithelium by an inflammatory infiltrate. 
Cytogenetics 
Three distinct groups of WT have been defined based 
on cytogenetic aberrations: one with a normal 
karyotype, a second with numerical changes only (loss 
of Y chromosome or trisomy or monosomy 5), and a 
third group involving structural changes with one or 
two reciprocal translocations. Two neoplasms have 
been reported to carry a t(11;19)(q21;p13) 
translocation, suggesting a link to mucoepidermoid 
carcinoma. The translocation was present either as the 
sole karyotypic anomaly or as part of a more complex 
karyotype. The case displaying a complex karyotype 
carried a MECT1-MAML2 fusion transcript. In another 
series, 4 out of 11 WT cases (36%) also harbored that 
fusion transcript. A recent independent study reported 
that 2 out of 48 cases (4%) expressed the MECT1-
MAML2 fusion transcript, and that both cases were 
metaplastic variants of WT. But, on review, the tumors 
were reclassified by the same investigators as highly 
suspect for MEC. The remaining 46 neoplasms were 
definitely classic WTs and none displayed the fusion 
transcript. Hence, morphologically ambiguous cases of 
WT exhibiting the MECT1-MAML2 chimeric gene 
should be regarded with caution. 
Treatment 
In Warthin tumor, radical surgical excision (either 
superficial parotidectomy or enucleation) is curative. 
Prognosis 
Recurrence rates are low, at about 2-5.5%; recurrence 
presumably results from multifocality. 
Disease 
Mucoepidermoid carcinoma (MEC) 
Clinics 
In the major salivary glands, MEC usually presents as a 
solitary painless lesion. Similarly to other malignant 
neoplasms, over 50% of patients have been aware of 
the tumor for less than 6 months. Two thirds of 
individuals are asymptomatic. Some patients report 
rapid growth of the mass; others experience pain, 
dysphagia, trismus, and facial paralysis. In minor 
salivary glands, 40% of patients are symptomatic, 
suffering from pain, numbness of teeth, dysphagia, 
ulceration, and haemorrhage. 
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Mucoepidermoid carcinoma HEx400. 
Pathology 
MEC is the most common type of malignant SGTs, 
accounting for about 35% of salivary gland cancers. 
About 50% arise in the major salivary glands. MEC 
comprises epidermoid cells, mucus-producing cells, 
and so-called intermediate cells. It is usually 
multicystic with a solid component. Cystic spaces are
lined by mucous cells associated with a variable 
number of intermediate cells and a few epidermoid 
cells. Intermediate cells usually predominate and form 
clusters or solid sheets. Keratinisation is rarely seen. 
The borders of the lesion may appear well-defined but 
infiltration of adjacent gland parenchyma is most often 
obvious.  
MECs are classified as low-, intermediate- or high-
grade tumors depending on the presence or absence of 
the following criteria: 1) neural invasion, 2) necrosis, 3) 
anaplasia, 4) ≥ 4 mitoses per 10 high power fields, and 
5) less than 20% cystic spaces relative to solid areas. 
All these histopathological features are indicative of a 
more aggressive neoplasm. 
Histogenesis: Mucoepidermoid carcinoma may 
originate from excretory duct reserve cells, but the 
issue remains moot. 
Cytogenetics 
Even though MEC is the most common type of 
malignant SGTs, its pathogenesis and the key 
molecular events leading to its development are yet to 
unravel. At least two partially overlapping cytogenetic 
subgroups have been identified, i.e. MECs with 
t(11;19)(q21;p13) or variants thereof, and MECs with 
single or multiple trisomies, either observed as the sole 
abnormality or in combination with structural 
rearrangements.  
A recurrent t(11;19)(q21;p13) translocation has been 
identified in MECs of both salivary gland and 
bronchopulmonary origin. Such a translocation leads to 
the fusion of exon 1 from a gene of unknown function 
at 19p13, termed mucoepidermoid carcinoma 
translocated 1 (MECT1, also known as CTRC1, 
TORC1, or WAMTP1), with exons 2-5 of a member of 
mastermind-like gene family, MAML2, at 11q21. It has 
been demonstrated that the resultant fusion transcript 
MECT1-MAML2 activated transcription of the Notch 
target gene HES1 independently of ligand stimulation.  
The translocation t(11;19)(q21;p13) and the MECT1-
MAML2 fusion transcript have been detected in 38-
81% of MEC cases. The translocation is shared by 
acute leukemia, and an apparently identical 
rearrangement has been identified in WT. Apart from 
WT, it has not been demonstrated in any other salivary 
gland tumor. Immunohistochemistry using an MECT1-
MAML2 antibody in fusion-positive MECs resulted in 
nuclear staining of all three major cell types, i.e. 
mucus-producing, epidermoid, and intermediate cells. 
However, stromal cells did not express the fusion 
protein. Expression of the hybrid gene in all cell types 
suggests that it may play a role early in tumor 
initiation. Such a distinct translocation and resulting 
fusion transcript may be a useful tool in diagnosing 
morphologically ambiguous MEC. In addition, there is 
an association between transcript expression and tumor 
stage, with fusion-positive tumors behaving in a less 
aggressive fashion. Fusion-positive patients had a 
significantly lower risk of local recurrence, metastases, 
or tumor-related death compared to fusion-negative 
ones (median survival of more than 10 years compared 
to 1.6 years). In addition, there was a preponderanc  of 
highly differentiated low-grade tumors in fusion-
positive patients compared to the fusion-negative 
group. 
In one study, more than 55% of the MEC cases 
expressed the MECT1-MAML2 fusion transcript, 
indicating that the fusion is more common than 
suggested by conventional cytogenetic analysis. Not all 
fusion-positive tumors carried the translocation 
t(11;19), meaning that other cryptic translocations may 
contribute to the disease in such cases. Several cases 
displayed cryptic 11;19 rearrangements and MECT1-
MAML2 gene fusions. Fusions may thus be found in 
MECs with complex 11;19 rearrangements and in 
tumors with variant translocations such as t(11;17) and 
t(11;13), as well as in tumors with apparently normal 
karyotypes and trisomies.  
The second most common chromosomal abnormality 
was single or multiple trisomies, observed in 7 of 21 
MECs in one series. Trisomies were mostly observed in 
cases not harboring a t(11;19). The most frequently 
encountered trisomies were +7, +8, and +X. Other 
recurrent abnormalities found were deletions of the
terminal part of 6q. Apart from these abnormalities, the 
t(11;19)-negative MECs showed a heterogeneous 
pattern of rearrangements with no obvious recurrent 
aberrations. 
Very recently, deletions of CDKN2A gene have been 
shown to be associated with poor prognosis in MECT1-
MAML2 fusion-positive MECs. In the same study, 
neither activating EGFR mutations nor copy number 
gains at the EGFR locus was detected in fusion-positive 
and fusion-negative cases. Finally, detection of HER-2 
overexpression by immunohistochemistry has been 
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correlated to adverse clinicopathologic features in 
several studies. 
Treatment 
Mucoepidermoid carcinoma is treated by wide local 
surgical excision, followed by radiation therapy in case 
of inadequate surgical margins or pejorative 
microscopic features (e.g. neural invasion). 
Classification into high-grade and low-grade tumors 
guides treatment but the behavior of intermediate-grade 
neoplasms remains difficult to predict. 
Prognosis 
The 5- and 10-year survival rates are about 35% and 
10-20%, respectively. Presence of distant metastases 
portends poor prognosis. 
Disease 
Acinic cell carcinoma 
Clinics 
Acinic cell carcinoma is a low-grade malignant 
neoplasm that constitutes approximately 17% of SGTs 
and mostly develops in the parotid gland (80%). 
Seventeen percent arise in the intraoral minor salivary 
glands (buccal mucosa, upper lip); 4% develop in the 
submandibular glands and less  
than 1%, in the sublingual glands. It is the second most 
common epithelial malignancy of salivary glands after 
mucoepidermoid carcinoma. Women are more often 
affected than men. All age groups can be affected with 
an even distribution of patients from the second to the 
seventh decade. It usually presents as a slowly 
enlarging mass 1 to 3 cm in greatest dimension. It may
rarely be multinodular or fixed to skin or adjacent soft 
tissues. Acinic cell carcinoma is the malignancy of 
salivary glands that most often occurs bilaterally. 
About 30% of patients experience pain and less than
10% develop facial paralysis. At the time of diagnosis, 
signs and symptoms have usually been present for less 
than a year. 
 
Acinic cell carcinoma HEx200. 
Pathology 
Acinic cell carcinoma is a malignant neoplasm 
demonstrating serous acinar cell differentiation which 
is characterized by cytoplasmic zymogen secretory 
granules. Acinar cells are large, polygonal with lightly 
basophilic, granular cytoplasm and round, eccentric 
nucleus. The cytoplasmic zymogen secretory granules 
are PAS-positive, resistant to diastase digestion, and
non-reactive or only weakly reactive to mucicarmine 
stain. Several cell types and growth patterns can be 
observed: acinar, intercalated ductal, vacuolated, clear, 
and non-specific glandular and solid/lobular, 
microcystic, papillary-cystic, and follicular growth 
patterns. Even though one component may predominate 
(usually acinar cells and intercalated duct-like cells), 
many tumors harbor a combination of different cell 
types and architectures. In the follicular pattern, thyroid 
follicle-like structures filled with an eosinophilic 
proteinaceous material are present. Some features have 
been associated with a more aggressive biological 
behavior such as cellular pleomorphism, frequent 
mitoses, focal necrosis, neural invasion, infiltration, 
and stromal hyalinisation.  
Histogenesis: Acinic cell carcinoma may arise from 
neoplastic transformation of the terminal duct cells 
(intercalated duct cells) with differentiation toward 
serous acinar cells. Another theory posits that it could 
arise from transformation of terminally differentiated 
serous acinar cells. 
Cytogenetics 
Multiple structural and numerical aberrations have be n 
described in acinic cell carcinoma but no specific 
alteration has been identified. Loss of Y and trisomy 7, 
8, and 21 have been reported. In the largest study to 
date, 21 (84%) of the 25 acinic cell carcinomas showed 
LOH (loss of heterozygosity) in at least one of the20 
loci tested on chromosomes 1, 4, 5, 6, and 17. 
Chromosomal arms 4p, 5q, 6p, and 17p were the most 
frequently altered, with 4p15-16, 6p25-qter, and 17p11 
regions showing the highest rate of abnormalities. In 
another study, analysis of different samples from a 
single case found evidence of polyclonality. 
Treatment 
Surgical excision is the mainstay of treatment in acinic 
cell carcinoma. Radiation therapy may be indicated in 
some cases. 
Prognosis 
Acinic cell carcinoma tends to recur (35% of cases) and 
metastasize to cervical lymph nodes and later in the 
disease, to the lungs. Large size, incomplete resection, 
multiple recurrences, and lymph node metastases are 
associated with a poor prognosis. The rate of disease-
associated death is about 16%. While tumors in the 
submandibular gland are more aggressive than those in  
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the parotid gland, acinic cell carcinomas in minor 
salivary glands are less aggressive than those in the 
major salivary glands. 
Disease 
Adenoid cystic carcinoma 
Clinics 
Adenoid cystic carcinoma manifests as a slowly 
growing mass often accompanied by pain and in some 
cases, facial paralysis. 
 
Adenoid cystic carcinoma HEx200. 
Pathology 
Adenoid cystic carcinoma is an epithelial malignancy 
composed of epithelial and myoepithelial cells variably 
arranged in tubular, cribriform, and solid patterns. The 
cribriform pattern, which is the most common, is 
characterized by nests of cells containing small, 
circular cyst-like spaces. The solid pattern is associated 
with a poor prognosis compared to the tubular and 
cribriform architecture. Neural invasion is a hallmark 
of this entity, and often extends beyond the main tumor 
mass. Infiltration of adjacent soft tissues is also 
characteristic of adenoid cystic carcinoma. 
Cytogenetics 
Adenoid cystic carcinoma is characterized by a 
t(6;9)(q22-23;p23-24) translocation. The translocation 
fuses exon 14 of MYB gene, on chromosome 6q22-23, 
to the last coding exons of NFIB gene, on chromosome 
9p23-24. Most breakpoints occur in intron 14 of MYB 
and intron 8 of NFIB. The minimal common part of 
MYB that is deleted is exon 15 including the 3'-UTR 
which contains several highly conserved target sites for 
miR15a/16 and miR-150 microRNAs. These 
microRNAs are known to negatively regulate MYB 
expression. Deletion of these target sites may leadto 
overexpression of MYB-NFIB transcript and activation 
of MYB targets, including genes associated with 
apoptosis, cell cycle control, cell growth/angiogenesis, 
and cell adhesion. Deregulation of expression of MYB 
and its target genes may be a key oncogenic event in 
the pathogenesis of adenoid cystic carcinoma.  
Mutations in the c-kit gene have recently been 
described in adenoid cystic carcinoma, but their 
occurrence is rare, and they most probably do not 
represent driver mutations in this entity. 
Treatment 
Treatment of adenoid cystic carcinoma consists of wide 
local and radical surgical resection with or without 
radiation therapy, but the disease is usually relentless. 
Prognosis 
Most patients (80-90%) die of disease within 10 to 15 
years. The solid pattern is associated with a worse 
prognosis compared to the tubular or cribriform 
architecture. The prognostic value of neural invasion is 
debated. 
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